Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO ODT versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO ODT versus QUILLIVANT XR.
EVEKEO ODT vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant